IBB241004C147500
- 0.80
- 0.000.00%
iShares Biotechnology ETF Newsroom
(AMGN) - Analyzing Amgen's Short Interest
Roche Sees Carmot Obesity Drugs' Potential Peak Sales at $3.6B+: Report
$100 Invested In This Stock 5 Years Ago Would Be Worth $400 Today
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Monday Ahead of Powell's Speech on Economic Outlook
Reported Earlier, Alnylam's Vutrisiran Data Highlights Early Impact on Key Cardiac Biomarkers, Alnylam Eyes First-Line Therapy for ATTR Amyloidosis
Regeneron Pharma, Super Micro Computer And Global Payments Are Among Top 10 Large Cap Losers Last Week (Sept 23-Sept 27): Are The Others In Your Portfolio?
Stocks With the Highest Consensus of Expected ROE Growth, Goldman Sachs Says
Novo Nordisk's Ozempic, Regeneron/Sanofi's Dupixent Set to Advance in Top Drug Sales
Here Are the Medicare Part D Drugs Expected to Face 2025 Price Negotiations
Notable Analyst Calls This Week: Microsoft, Starbucks and GM Among Top Picks
Weekend Reading | Regenerative materials move towards becoming a billion-dollar giant
For a deeper understanding of how Rebirth Element has come to this day and the expected future growth.
Cantor Highly Bullish on Amgen Obesity Drug, Starts Coverage at Overweight
Regeneron Pharmaceuticals Announces Dupixent Approved In The U.S. As The First-Ever Biologic Medicine For Patients With COPD
Looking Into Alnylam Pharmaceuticals's Recent Short Interest
Peeling Back The Layers: Exploring Argenx Through Analyst Insights
Argenx Analyst Ratings
Sector Update: Health Care Stocks Edge Higher Premarket Thursday
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday as Tech Stocks Lead Rally
Biogen to End Sage Deal for Neuro Candidate
Roche, Biogen Kidney Disease Drug Hits Main Goal in Late-stage Study